<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chemotherapy for children with medulloblastoma - Michiels, EMC - 2015 | Cochrane Library</title> <meta content="Chemotherapy for children with medulloblastoma - Michiels, EMC - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006678.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chemotherapy for children with medulloblastoma - Michiels, EMC - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006678.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006678.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Chemotherapy for children with medulloblastoma" name="citation_title"/> <meta content="Erna MC Michiels" name="citation_author"/> <meta content="Erasmus MC ‐ Sophia Children's Hospital" name="citation_author_institution"/> <meta content="e.michiels@erasmusmc.nl" name="citation_author_email"/> <meta content="Antoinette YN Schouten‐Van Meeteren" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="François Doz" name="citation_author"/> <meta content="Geert O Janssens" name="citation_author"/> <meta content="Radboud University Nijmegen Medical Centre" name="citation_author_institution"/> <meta content="Elvira C van Dalen" name="citation_author"/> <meta content="Emma Children's Hospital/Academic Medical Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD006678.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/01/01" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006678.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006678.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006678.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Cerebellar Neoplasms [*drug therapy, mortality, radiotherapy]; Disease‐Free Survival; Medulloblastoma [*drug therapy, mortality, radiotherapy]; Radiotherapy Dosage; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006678.pub2&amp;doi=10.1002/14651858.CD006678.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xsb6SJyC";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006678\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006678\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006678.pub2",title:"Chemotherapy for children with medulloblastoma",firstPublishedDate:"Jan 1, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Childhood Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006678.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006678.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006678.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006678.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006678.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006678.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006678.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006678.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006678.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006678.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3423 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006678.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-sec-0067"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-sec-0015"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-sec-0016"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-sec-0035"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-sec-0064"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/appendices#CD006678-sec-0074"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/table_n/CD006678StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/table_n/CD006678StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chemotherapy for children with medulloblastoma</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information#CD006678-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Erna MC Michiels</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information#CD006678-cr-0003">Antoinette YN Schouten‐Van Meeteren</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information#CD006678-cr-0004">François Doz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information#CD006678-cr-0005">Geert O Janssens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information#CD006678-cr-0006">Elvira C van Dalen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information/en#CD006678-sec-0079">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 01 January 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006678.pub2">https://doi.org/10.1002/14651858.CD006678.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006678-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006678-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006678-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006678-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006678-abs-0001" lang="en"> <section id="CD006678-sec-0001"> <h3 class="title" id="CD006678-sec-0001">Background</h3> <p>Post‐surgical radiotherapy (RT) in combination with chemotherapy is considered as standard of care for medulloblastoma in children. Chemotherapy has been introduced to improve survival and to reduce RT‐induced adverse effects. Reduction of RT‐induced adverse effects was achieved by deleting (craniospinal) RT in very young children and by diminishing the dose and field to the craniospinal axis and reducing the boost volume to the tumour bed in older children. </p> </section> <section id="CD006678-sec-0002"> <h3 class="title" id="CD006678-sec-0002">Objectives</h3> <p>Primary objectives: 1. to determine the event‐free survival/disease‐free survival (EFS/DFS) and overall survival (OS) in children with medulloblastoma receiving chemotherapy as a part of their primary treatment, as compared with children not receiving chemotherapy as part of their primary treatment; 2. to determine EFS/DFS and OS in children with medulloblastoma receiving standard‐dose RT without chemotherapy, as compared with children receiving reduced‐dose RT with chemotherapy as their primary treatment. </p> <p>Secondary objectives: to determine possible adverse effects of chemotherapy and RT, including long‐term adverse effects and effects on quality of life. </p> </section> <section id="CD006678-sec-0003"> <h3 class="title" id="CD006678-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2013, Issue 7), MEDLINE/PubMed (1966 to August 2013) and EMBASE/Ovid (1980 to August 2013). In addition, we searched reference lists of relevant articles, conference proceedings and ongoing trial databases (August 2013). </p> </section> <section id="CD006678-sec-0004"> <h3 class="title" id="CD006678-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) evaluating the above treatments in children (aged 0 to 21 years) with medulloblastoma. </p> </section> <section id="CD006678-sec-0005"> <h3 class="title" id="CD006678-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed study selection, data extraction and risk of bias assessment. We performed analyses according to the guidelines of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>. Where possible, we pooled results. </p> </section> <section id="CD006678-sec-0006"> <h3 class="title" id="CD006678-sec-0006">Main results</h3> <p>The search identified seven RCTs, including 1080 children, evaluating treatment including chemotherapy and treatment not including chemotherapy. The meta‐analysis of EFS/DFS not including disease progression during therapy as an event in the definition showed a difference in favour of treatment including chemotherapy (hazard ratio (HR) 0.70; 95% confidence interval (CI) 0.54 to 0.91; P value = 0.007; 2 studies; 465 children). However, not including disease progression as an event might not be optimal and the finding was not confirmed in the meta‐analysis of EFS/DFS including disease progression during therapy as an event in the definition (HR 1.02; 95% CI 0.70 to 1.47; P value = 0.93; 2 studies; 300 children). Two individual studies using unclear or other definitions of EFS/DFS also showed no clear evidence of difference between treatment arms (one study with unclear definition of DFS: HR 1.67; 95% CI 0.59 to 4.71; P value = 0.34; 48 children; one study with other definition of EFS: HR 0.84; 95% CI 0.58 to 1.21; P value = 0.34; 233 children). In addition, it should be noted that in one of the studies not including disease progression as an event, the difference in DFS only reached statistical significance while the study was running, but due to late relapses in the chemotherapy arm, this significance was no longer evident with longer follow‐up. There was no clear evidence of difference in OS between treatment arms (HR 1.06; 95% CI 0.67 to 1.67; P value = 0.80; 4 studies; 332 children). Out of eight reported adverse effects, of which seven were reported in one study, two (severe infections and fever/neutropenia) showed a difference in favour of treatment not including chemotherapy (severe infections: risk ratio (RR) 5.64; 95% CI 1.28 to 24.91; P value = 0.02; fever/neutropenia: RR not calculable; Fisher's exact P value = 0.01). There was no clear evidence of a difference between treatment arms for other adverse effects (acute alopecia: RR 1.00; 95% CI 0.92 to 1.08; P value = 1.00; reduction in intelligence quotient: RR 0.78; 95% CI 0.46 to 1.30; P value = 0.34; secondary malignancies: Fisher's exact P value = 0.5; haematological toxicity: RR 0.54; 95% CI 0.20 to 1.45; P value = 0.22; hepatotoxicity: Fisher's exact P value = 1.00; treatment‐related mortality: RR 2.37; 95% CI 0.43 to 12.98; P value = 0.32; 3 studies). Quality of life was not evaluated. In individual studies, the results in subgroups (i.e. younger/older children and high‐risk/non‐high‐risk children) were not univocal. </p> <p>The search found one RCT comparing standard‐dose RT with reduced‐dose RT plus chemotherapy. There was no clear evidence of a difference in EFS/DFS between groups (HR 1.54; 95% CI 0.81 to 2.94; P value = 0.19; 76 children). The RCT did not evaluate other outcomes and subgroups. </p> <p>The presence of bias could not be ruled out in any of the studies.</p> </section> <section id="CD006678-sec-0007"> <h3 class="title" id="CD006678-sec-0007">Authors' conclusions</h3> <p>Based on the evidence identified in this systematic review, a benefit of chemotherapy cannot be excluded, but at this moment we are unable to draw a definitive conclusion regarding treatment with or without chemotherapy. Treatment results must be viewed in the context of the complete therapy (e.g. the effect of surgery and craniospinal RT), and the different chemotherapy protocols used. This systematic review only allowed a conclusion on the concept of treatment, not on the best strategy regarding specific chemotherapeutic agents and radiation dose. Several factors complicated the interpretation of results including the long time span between studies with important changes in treatment in the meantime. 'No evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. The fact that no significant differences between treatment arms were identified could, besides the earlier mentioned reasons, also be the result of low power or too short a follow‐up period. Even though RCTs are the highest level of evidence, it should be recognised that data from non‐randomised studies are available, for example on the use of chemotherapy only in very young children with promising results for children without metastatic disease. We found only one RCT addressing standard‐dose RT without chemotherapy versus reduced‐dose RT with chemotherapy, so no definitive conclusions can be made. More high‐quality research is needed. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006678-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006678-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006678-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006678-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD006678-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006678-abs-0004">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006678-abs-0003" lang="en"> <h3>Chemotherapy for children with medulloblastoma</h3> <p><b>Background</b> </p> <p>Medulloblastoma is one of the most common malignant brain tumours in children. Chemotherapy is used to improve survival and diminish potential radiotherapy‐induced side effects. The reduction of radiotherapy‐induced side effects is achieved in very young children by not treating them with radiotherapy and in older children by diminishing the craniospinal radiotherapy (radiotherapy applied to the brain and spinal cord) dose and by reducing the boost volume to the tumour bed only instead of the whole posterior fossa (part of the brain). A well‐informed decision on the use of chemotherapy in the treatment of medulloblastoma in children should be based on high‐quality evidence on both the effectiveness against the tumour and side effects. </p> <p><b>Study characteristics</b> </p> <p>We searched databases for randomised trials (studies where participants are allocated to one of two or more treatment groups in a random manner) evaluating the effectiveness of treatment including chemotherapy versus treatment not including chemotherapy (seven available studies) and on randomised studies evaluating the effectiveness of standard‐dose radiotherapy without chemotherapy versus reduced‐dose radiotherapy plus chemotherapy (one available study) in children (aged 0 to 21 years). The evidence is current to August 2013. </p> <p><b>Key results and quality of the evidence</b> </p> <p>Based on the evidence identified in this systematic review a benefit of chemotherapy cannot be excluded, but at this moment we are unable to draw a definitive conclusion to favour treatment with or without chemotherapy. Even though randomised studies are the highest level of evidence, it should be recognised that data from non‐randomised studies were available, for example on the use of chemotherapy only in very young children. The results are promising for children without metastatic disease. For treatment with standard‐dose radiotherapy without chemotherapy as compared with reduced‐dose radiotherapy with chemotherapy, we also cannot make definitive recommendations. More high‐quality research is needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006678-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006678-sec-0067"></div> <h3 class="title" id="CD006678-sec-0068">Implications for practice</h3> <section id="CD006678-sec-0068"> <section id="CD006678-sec-0069"> <h5 class="title">Treatment including chemotherapy compared with treatment not including chemotherapy</h5> <p>Only the meta‐analysis of event‐free survival/disease‐free survival (EFS/DFS), not including disease progression during therapy in the definition, showed a significant difference in favour of treatment including chemotherapy. This finding was not confirmed in either the meta‐analysis of EFS/DFS including disease progression during therapy in the definition or individual randomised controlled trials (RCTs) using unclear or other definitions of EFS/DFS (which showed no significant difference between treatment arms). The discordance between these results is difficult to explain. Not including disease progression as an event might not be optimal. We identified no significant difference in overall survival (OS) between treatment arms. Data on adverse effects were scarce. Out of eight reported adverse effects, of which seven were reported in one study only, severe infections and fever/neutropenia showed a significant difference in favour of treatment not including chemotherapy. For the other adverse effects, there was no significant difference between treatment arms. No information on quality of life was provided. In addition, we can make no definitive conclusions regarding the effect of treatment including and not including chemotherapy in different subgroups. However, two studies show that children with advanced disease might have an improved EFS/DFS when receiving chemotherapy, but we could not pool the results and also, some definitions of advanced disease as used in the included studies differed from the currently used definitions. The results of this systematic review must be viewed in the context of the complete therapy (e.g. the effect of surgery and craniospinal radiotherapy, and the different chemotherapy protocols used). Thus, this systematic review only allows a conclusion on the concept of treatment including chemotherapy versus treatment not including chemotherapy; we can make no conclusions regarding the best treatment strategy. </p> <p>Several factors complicated the interpretation of results: different definitions of study end points, numerous chemotherapy regimens and doses, a long time span between the first and the last studies with important changes in supportive care and progress in imaging and treatment techniques in the meantime, no information on histological subtypes and molecular characteristics of the tumour, no uniform definition of standard‐risk versus high‐risk children and the fact that in most studies different risk groups were not analysed separately. In addition, the fact that we identified no significant differences between treatment arms could be, for example, the result of low power or too short a follow‐up period. Based on the currently available evidence, we are unable to determine whether treatment with or without chemotherapy in children with medulloblastoma is preferable. </p> </section> <section id="CD006678-sec-0070"> <h5 class="title">Treatment with standard‐dose radiotherapy compared with treatment with reduced‐dose radiotherapy and chemotherapy </h5> <p>Since we identified only one RCT comparing standard‐dose radiotherapy with reduced‐dose radiotherapy and chemotherapy, no definitive conclusions can be made about these treatments. In this small study group of 76 children, there was no significant difference in EFS/DFS, but this finding should be confirmed in other RCTs. The study did not report on OS, adverse effects and quality of life. </p> </section> </section> <h3 class="title" id="CD006678-sec-0071">Implications for research</h3> <section id="CD006678-sec-0071"> <p>In order to state with a high level of certainty if and for which children the addition of chemotherapy (with or without reduced‐dose radiotherapy) to the previous standard therapy of radiation only will improve treatment results in children with medulloblastoma, we need high‐quality RCTs in which uniform stratification criteria for standard‐risk and high‐risk children are used, as well as uniform outcome definitions (including EFS/DFS, OS, adverse effects and quality of life). However, in the current treatment era, it is considered unethical to use RCTs of the former higher 'standard‐dose' radiotherapy in one arm, as the long‐term consequences are devastating. Thus, it is very unlikely that such high‐quality RCTs will be developed in the future. It is widely recognised that an RCT is the only study design that can provide unbiased evidence on interventions, provided that the design and execution are adequate. Without evidence from high‐quality RCTs, we have to acknowledge that the true efficacy of these treatments in children with medulloblastoma remains unclear. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006678-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006678-sec-0015"></div> <p>Medulloblastoma represents one of the most common malignant brain tumours in childhood, occurring mostly in children younger than 10 years of age. Survival of children with medulloblastoma is correlated with the age at diagnosis, the presence of metastatic disease, the treatment given and the presence of extensive residual disease following neurosurgery. Five‐year event‐free survival (EFS) varies from around 30% to more than 80% (<a href="./references#CD006678-bbs2-0028" title="KortmannRD , KühlJ , TimmermannB , MittlerU , UrbanC , BudachV , et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT 91. International Journal of Radiation Oncology, Biology and Physics2000;46(2):269‐79. ">Kortmann 2000</a>; <a href="./references#CD006678-bbs2-0048" title="ZeltzerPM , BoyetJM , FinlayJL , AlbrightAL , RorkeLB , MilsteinJM , et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. Journal of Clinical Oncology1999;17(3):832‐45. ">Zeltzer 1999</a>). More recently, the histological subtypes and molecular characteristics of the tumour were added as prognostic markers. While nodular/desmoplastic tumours appear to have a favourable prognosis (<a href="./references#CD006678-bbs2-0044" title="RutkowskiS , VonHoffK , EmserA , ZwienerI , PietschT , Figarella‐BrangerD , et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta‐analysis. Journal of Clinical Oncology2010;28(33):4961‐8. ">Rutkowski 2010</a>), children with large cell/anaplastic medulloblastoma have a poor prognosis (<a href="./references#CD006678-bbs2-0014" title='BrownHG , KepnerJL , PerlmanEJ , FriedmanHS , StrotherDR , DuffnerPK , et al. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. Journal of Neuropathology and Experimental Neurology2000;59(10):857‐65. '>Brown 2000</a>; <a href="./references#CD006678-bbs2-0017" title="EllisonDW , OniludeOE , LindseyJC , LusherME , WestonCL , TaylorRE , et al. Beta‐catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology2005;23(31):7951‐7. ">Ellison 2005</a>; <a href="./references#CD006678-bbs2-0018" title="GajjarA , ChintagumpalaM , AshleyD , KellieS , KunLE , MerchantTE , et al. Risk‐adapted craniospinal radiotherapy followed by high‐dose chemotherapy and stem‐cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma‐96): long‐term results from a prospective, multicentre trial. Lancet Oncology2006;7:813‐20. ">Gajjar 2006</a>; <a href="./references#CD006678-bbs2-0021" title="GiangasperoF , PerilongoG , FondelliMP , BrisigottiM , CarolloC , BurnelliR , et al. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. Journal of Neurosurgery1999;91(6):971‐7. ">Giangaspero 1999</a>; <a href="./references#CD006678-bbs2-0024" title="GrotzerMA , HogartyMD , JanssAJ , LiuX , ZhaoH , EggertA , et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clinical Cancer Research2001;7:2425‐33. ">Grotzer 2001</a>; <a href="./references#CD006678-bbs2-0033" title="NorthcottPA , KorshunovA , WittH , HielscherT , EberhartCG , MackS . Medulloblastoma comprises four distinct molecular variants. Journal of Clinical Oncology2011;29(11):1408‐14. ">Northcott 2011</a>). Molecular characteristics with a favourable prognosis are nuclear expression of beta‐catenin (<a href="./references#CD006678-bbs2-0017" title="EllisonDW , OniludeOE , LindseyJC , LusherME , WestonCL , TaylorRE , et al. Beta‐catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. Journal of Clinical Oncology2005;23(31):7951‐7. ">Ellison 2005</a>; <a href="./references#CD006678-bbs2-0018" title="GajjarA , ChintagumpalaM , AshleyD , KellieS , KunLE , MerchantTE , et al. Risk‐adapted craniospinal radiotherapy followed by high‐dose chemotherapy and stem‐cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma‐96): long‐term results from a prospective, multicentre trial. Lancet Oncology2006;7:813‐20. ">Gajjar 2006</a>), and TrkC expression (<a href="./references#CD006678-bbs2-0023" title="GrotzerMA , JanssAJ , FungKM , BiegelJA , SuttonLN , RorkeLB , et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. Journal of Clinical Oncology2000;18(5):1027‐35. ">Grotzer 2000</a>; <a href="./references#CD006678-bbs2-0043" title="RutkowskiS , vonBuerenA , vonHoffK , HartmannW , ShalabyT , DeinleinF , et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clinical Cancer Research2007;13(9):2651‐7. ">Rutkowski 2007</a>); a worse prognosis is related to MYC/MYCN amplification (<a href="./references#CD006678-bbs2-0039" title="PfisterS , RemkeM , BennerA , MendrzykF , ToedtG , FelsbergJ , et al. Outcome prediction in pediatric medulloblastoma based on DNA copy‐number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. Journal of Clinical Oncology2009;27(10):1627‐36. ">Pfister 2009</a>). Four main subgroups of medulloblastoma exist; Wnt (very good prognosis), Shh (intermediate prognosis), Group 3 (poor prognosis) and Group 4 (intermediate prognosis) (<a href="./references#CD006678-bbs2-0047" title="TaylorMD , NorthcottPA , KorshunovA , RemkeM , ChoY , CliffordSC , et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica2012;123:465‐72. ">Taylor 2012</a>). </p> <p>For decades, the standard therapy for children with medulloblastoma has been neurosurgery with a maximum of debulking, followed by craniospinal radiotherapy (CSRT). However, craniospinal irradiation causes significant long‐term adverse effects. Children aged less than 36 months who received whole‐brain radiotherapy (cranial radiotherapy (CRT)) as part of their treatment of a cerebellar tumour showed more neurocognitive and psychosocial deficits than non‐irradiated infants (<a href="./references#CD006678-bbs2-0016" title="CopelandD , deMoorC , MooreB , AterJ . Neurocognitive development of children after a cerebellar tumor in infancy: a longitudinal study. Journal of Clinical Oncology1999;17(11):3476‐86. ">Copeland 1999</a>). Palmer et al. found that the decline in intelligence quotient (IQ) values was the result of an inability to acquire new skills and information at a rate comparable to their healthy peers, and not to a loss of previously acquired information and skills (<a href="./references#CD006678-bbs2-0037" title="PalmerS , GoloubevaO , ReddickW , GlassJ , GajjarA , KunL , et al. Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. Journal of Clinical Oncology2001;19(8):2302‐8. ">Palmer 2001</a>). On the endocrinological level, deficiencies following CSRT have been known for a very long time (<a href="./references#CD006678-bbs2-0031" title="LiveseyEA , HindmarshPC , BrookCG , WhittonAC , BloomHJ , TobiasJS , et al. Endocrine disorders following treatment of childhood brain tumours. British Journal of Cancer1990;61:622‐5. ">Livesey 1990</a>; <a href="./references#CD006678-bbs2-0045" title="ShaletSM , BeardwellCG , MacFarlaneIA , JonesPH , PearsenD . Endocrine morbidity in adults treated with cerebral irradiation for brain tumours during childhood. Acta Endocrinologica1977;84:673‐80. ">Shalet 1977</a>). In accordance, Spoudeas et al. showed that growth hormone is especially sensitive to radiation injury (<a href="./references#CD006678-bbs2-0046" title="SpoudeasH , CharmandariE , BrookC . Hypothalamo‐pituitary‐adrenal axis integrity after cranial irradiation for childhood posterior fossa tumours. Medical and Pediatric Oncology2003;40:224‐9. ">Spoudeas 2003</a>), and Gurney et al. demonstrated hypothyroidism in 30% of irradiated participants and a growth hormone deficiency in 39.2% of irradiated participants (<a href="./references#CD006678-bbs2-0025" title="GurneyJ , Kadan‐LottickN , PackerR , NegliaJ , SklarC , PunykoJ , et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors. Cancer2003;97(3):663‐73. ">Gurney 2003</a>). </p> <p>As a consequence, chemotherapy has been introduced in older children to improve survival and diminish the long‐term effects caused by radiotherapy (RT), while in very young children, its goal is mainly to omit or delay RT, while preserving or even improving survival rates (<a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0020" title="GeyerJR , SpostoR , JenningsM , BoyettJM , AxtellRA , BreigerD , et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. Journal of Clinical Oncology2005;23:7621‐31. ">Geyer 2005</a>; <a href="./references#CD006678-bbs2-0022" title="GrillJ , Sainte‐RoseC , JouvetA , GentetJC , LejarsO , FrappazD , et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncology2005;6:573‐80. ">Grill 2005</a>; <a href="./references#CD006678-bbs2-0032" title="MerchantTE , KunLE , KrasinMJ , WallaceD , ChintagumpalaMM , WooSY , et al. Multi‐institution prospective trial of reduced‐dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose‐intensive chemotherapy for average‐risk medulloblastoma. International Journal of Radiation Oncology, Biology and Physics2008;70(3):782‐7. ">Merchant 2008</a>; <a href="./references#CD006678-bbs2-0034" title="Oyharcabal‐BourdenV , KalifaC , GentetJC , FrappazD , EdanC , ChastagnerP , et al. Standard‐risk medulloblastoma treated by adjuvant chemotherapy followed by reduced‐dose craniospinal radiation therapy: a French Society of Pediatric Oncology study. Journal of Clinical Oncology2005;23(19):4726‐34. ">Oyharcabal‐Bourden 2005</a>; <a href="./references#CD006678-bbs2-0035" title="PackerRJ , GajjarA , VezinaG , Rorke‐AdamsL , BurgerPC , RobertsonPL , et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average‐risk medulloblastoma. Journal of Clinical Oncology2006;24(25):4202‐8. ">Packer 2006</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>; <a href="./references#CD006678-bbs2-0042" title="RutkowskiS , BodeU , DeinleinF , OttensmeierH , Warmuth‐MetzM , SoerensenN , et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. New England Journal of Medicine2005;352:978‐86. ">Rutkowski 2005</a>). In recent years, high‐dose chemotherapy followed by stem cell rescue has been increasingly used for children with a poor prognosis (<a href="./references#CD006678-bbs2-0018" title="GajjarA , ChintagumpalaM , AshleyD , KellieS , KunLE , MerchantTE , et al. Risk‐adapted craniospinal radiotherapy followed by high‐dose chemotherapy and stem‐cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma‐96): long‐term results from a prospective, multicentre trial. Lancet Oncology2006;7:813‐20. ">Gajjar 2006</a>; <a href="./references#CD006678-bbs2-0019" title="GandolaL , MassiminoM , CefaloG , SoleroC , SpreaficoF , PecoriE , et al. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. Journal of Clinical Oncology2009;27(4):566‐71. ">Gandola 2009</a>; <a href="./references#CD006678-bbs2-0022" title="GrillJ , Sainte‐RoseC , JouvetA , GentetJC , LejarsO , FrappazD , et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncology2005;6:573‐80. ">Grill 2005</a>; <a href="./references#CD006678-bbs2-0040" title="Pérez‐MartinezA , QuinteroV , VicentMG , SevillaJ , DiazMA , MaderoL . High‐dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of Neuro‐Oncology2004;67:101‐6. ">Pérez‐Martinez 2004</a>). </p> <p>Several randomised controlled trials (RCT) have been conducted to analyse the effects of chemotherapy, and to detect possible subgroups of children that might benefit most from chemotherapy. However, until now, no systematic review had been carried out. </p> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006678-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006678-sec-0016"></div> <p>Primary objectives: 1. to determine the EFS/disease‐free survival (EFS/DFS) and overall survival (OS) in children with medulloblastoma receiving chemotherapy as a part of their primary treatment, as compared with children not receiving chemotherapy as part of their primary treatment; 2. to determine EFS/DFS and OS in children with medulloblastoma receiving standard‐dose RT without chemotherapy, as compared with children receiving reduced‐dose RT with chemotherapy as their primary treatment. </p> <p>Secondary objectives: to determine possible adverse effects of chemotherapy and RT, including long‐term adverse effects and effects on quality of life. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006678-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006678-sec-0017"></div> <section id="CD006678-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006678-sec-0019"> <h4 class="title">Types of studies</h4> <section id="CD006678-sec-0020"> <h5 class="title">Primary objective 1</h5> <p>RCTs comparing the EFS/DFS or OS (or both) in children with medulloblastoma receiving chemotherapy as part of their primary treatment compared with children not receiving chemotherapy as part of their primary treatment. </p> <p>As mentioned in the protocol of this review, we would only have included controlled clinical trials (CCTs) if we had identified no RCTs. </p> </section> <section id="CD006678-sec-0021"> <h5 class="title">Primary objective 2</h5> <p>RCTs comparing the EFS/DFS or OS (or both) in children with medulloblastoma receiving standard‐dose RT without chemotherapy compared with children receiving reduced‐dose RT with chemotherapy as their primary treatment. </p> <p>As mentioned in the protocol of this review, we would only have included CCTs if we had identified no RCTs. </p> </section> </section> <section id="CD006678-sec-0022"> <h4 class="title">Types of participants</h4> <p>Children (aged 0 to 21 years) with a primary diagnosis of medulloblastoma.</p> </section> <section id="CD006678-sec-0023"> <h4 class="title">Types of interventions</h4> <section id="CD006678-sec-0024"> <h5 class="title">Primary objective 1</h5> <p>Neurosurgery or RT (or both) with or without chemotherapy.</p> </section> <section id="CD006678-sec-0025"> <h5 class="title">Primary objective 2</h5> <p>Neurosurgery and standard‐dose RT (30 Gray (Gy) or greater on the craniospinal axis (CSA) and 50 Gy or greater on the posterior fossa) without chemotherapy or reduced‐dose RT (less than 30 Gy on the CSA and 50 Gy or greater on the posterior fossa) with chemotherapy. </p> </section> </section> <section id="CD006678-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD006678-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD006678-list-0001"> <li> <p>EFS/DFS, defined as the time to recurrence or progression of primary disease or death from any cause. </p> </li> <li> <p>OS, defined as the time to death from any cause.</p> </li> </ol> </p> </section> <section id="CD006678-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD006678-list-0002"> <li> <p>Adverse effects, defined as toxicities grade 3 or higher (as classified by, for example, the Common Toxicity Criteria of the World Health Organization (WHO)) and including long‐term adverse effects, such as neurocognitive impairment and endocrinological deficiencies (as defined by the authors of the original study). </p> </li> <li> <p>Quality of life.</p> </li> </ol> </p> </section> </section> </section> <section id="CD006678-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <p>We searched the following electronic databases:</p> <p> <ol id="CD006678-list-0003"> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 7);</p> </li> <li> <p>MEDLINE/PubMed (from 1966 to 6 August 2013);</p> </li> <li> <p>EMBASE/Ovid (from 1980 to 6 August 2013).</p> </li> </ol> </p> <p>The search strategies for the different electronic databases are shown in <a href="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1%26format=REVMAN#APP-01" target="_blank">Appendix 1</a>; <a href="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1%26format=REVMAN#APP-02" target="_blank">Appendix 2</a>; and <a href="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1%26format=REVMAN#APP-03" target="_blank">Appendix 3</a>. </p> <p>We handsearched the reference lists of relevant articles and review articles for information about trials, published or unpublished, not registered in CENTRAL, MEDLINE or EMBASE. We also scanned the conference proceedings of the International Society for Paediatric Oncology (SIOP), American Society for Pediatric Hematology and Oncology (ASPHO) and the International Symposium of Paediatric Neuro‐Oncology (ISPNO) from 2001 to 2008, if available electronically and otherwise by handsearching. We searched for ongoing trials by scanning the International Standard Randomised Controlled Trial Number (ISRCTN) register and the National Institutes of Health Register (<a href="http://www.controlled-trials.com" target="_blank">www.controlled‐trials.com</a>; both screened 15 August 2013). We applied no language restrictions. </p> </section> <section id="CD006678-sec-0030"> <h3 class="title" id="CD006678-sec-0030">Data collection and analysis</h3> <section id="CD006678-sec-0031"> <h4 class="title">Study identification</h4> <p>Two review authors independently identified studies meeting the inclusion criteria on grounds of the title or abstract (or both) and if necessary obtained the full‐text reports for closer inspection. We reported details of reasons for exclusion of any study considered for the review clearly in the <a href="./references#CD006678-sec-0086" title="">Characteristics of excluded studies</a> table. We resolved discrepancies by consensus and required no third‐party arbitration. We reported full details of included studies in the <a href="./references#CD006678-sec-0085" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD006678-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias in included studies according to the following criteria: concealment of treatment allocation; blinding of care provider, blinding of participants, blinding of outcome assessor (for each outcome separately); intention‐to‐treat (ITT) analyses (for each outcome separately) and completeness of follow‐up (for each outcome separately). We have used the definitions as described in the module of the Cochrane Childhood Cancer Group at the time of writing the protocol for this systematic review (see <a href="#CD006678-tbl-0001">Table 1</a>). We resolved discrepancies between review authors by consensus and required no third‐party arbitration. </p> <div class="table" id="CD006678-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for the assessment of risk of bias in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of bias item</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Implementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Adequate</i> : use of randomisation method that did not allow investigator and participant to know or influence the allocation of treatment before eligible participants entered the study<br/> <i>Inadequate</i> : use of alternate medical record numbers or unsealed envelopes as randomisation method, or there was information in the study indicating that investigators or participants could have influenced the allocation of treatment, or both<br/> <i>Unclear</i>: randomisation stated but no information on method used was available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinding of care providers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Performance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate information about blinding must have been provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinding of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Performance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate information about blinding must have been provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinding of outcome assessors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Detection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate information about blinding must have been provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intention‐to‐treat analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attrition bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Yes</i> : all participants were analysed in the treatment group to which they were randomised, regardless of whether or not they received the allocated intervention<br/> <i>No</i> : some participants (&lt; 5%, 5‐10%, 11‐20%, &gt; 20%) were not analysed in the treatment group to which they were randomised because they did not receive study intervention, they withdrew from the study or because of protocol violation<br/> <i>Unclear</i>: inability to determine if participants were analysed according to the intention‐to‐treat principle </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Completeness of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attrition bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percentage of participants excluded or lost to follow‐up (&lt; 5%, 5‐10%, 11‐20%, &gt; 20%) should be stated </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD006678-sec-0033"> <h4 class="title">Data extraction</h4> <p>Two review authors independently performed data extraction using standardised forms. We extracted data on: </p> <p> <ol id="CD006678-list-0004"> <li> <p>characteristics of participants (e.g. age, sex, tumour staging, histological subtype and molecular markers); </p> </li> <li> <p>characteristics of interventions (e.g. extent of surgical resection, posterior fossa and CSRT dose, type and dosage of chemotherapy, duration of chemotherapy, route of delivery of chemotherapy); </p> </li> <li> <p>characteristics of outcome measures (see <a href="#CD006678-sec-0026">Types of outcome measures</a>); </p> </li> <li> <p>duration of follow‐up.</p> </li> </ol> </p> <p>In cases of disagreement between review authors, we re‐examined the abstracts and articles and discussed findings until we achieved consensus. We required no third‐party arbitration. </p> </section> <section id="CD006678-sec-0034"> <h4 class="title">Data analysis</h4> <p>We entered data into Review Manager 5 (<a href="./references#CD006678-bbs2-0041" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>), and analysed data according to the guidelines of the Cochrane <i>Handbook for Systematic Reviews of Interventions</i> (<a href="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1%26format=REVMAN#REF-Higgins-2008" target="_blank">Higgins 2008</a>). For dichotomous variables, we calculated risk ratio (RR) and 95% confidence intervals (CI). For the assessment of survival, we used the generic inverse variance function of Review Manager 5 to combine logs of the hazard ratios (HRs) (<a href="./references#CD006678-bbs2-0041" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>) and reported 95% CI. We used Parmar's method if HRs had not been explicitly presented in the study (<a href="./references#CD006678-bbs2-0038" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>). We extracted data by allocation intervention, irrespective of compliance with the allocated intervention, in order to allow an ITT analysis. If it was not possible to perform an ITT analysis, we stated this. We assessed heterogeneity both by visual inspection of the forest plots and by a formal statistical test for heterogeneity (i.e. the I<sup>2</sup> statistic). If there was evidence of substantial heterogeneity (I<sup>2</sup> greater than 50%) (<a href="./references#CD006678-bbs2-0027" title="HigginsJPT , GreenS . Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. Chichester: John Wiley &amp; Sons, 2008. ">Higgins 2008</a>), we reported this. We used a random‐effects model for the estimation of treatment effects throughout the review. . We pooled data if we identified two or more studies, otherwise we summarised the results descriptively. For outcomes where only one study was available, we were unable to calculate an RR if one of the treatment arms experienced no events and we used the Fischer's exact test instead (calculated using GraphPad software; <a href="http://www.graphpad.com/quickcalcs/contingency1.cfm" target="_blank">www.graphpad.com/quickcalcs/contingency1.cfm</a>). Where possible, we separated data for younger/older children and high‐risk/non‐high‐risk children (i.e. subgroups). For all outcomes for which pooling was possible, we performed sensitivity analyses for all quality criteria separately. We excluded the low‐quality studies and the studies for which the quality was unclear and compared the results of the good‐quality studies with the results of all available studies. We considered the quality of studies included in the analyses in the interpretation of the results of the review. We planned to construct a funnel plot to ascertain graphically the existence of publication bias. However, generally, tests for funnel plot asymmetry should be used only when there are at least 10 studies included in the meta‐analysis, because when there are fewer studies the power of the tests is too low to distinguish chance from real asymmetry (<a href="http://www.archie.cochrane.org/sections/documents/view?document=A9AEFB8682E26AA200D4F13AB0F965A1%26format=REVMAN#REF-Higgins-2008" target="_blank">Higgins 2008</a>). Since only a maximum of four trials could be included in the different meta‐analyses, we did not construct funnel plots. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006678-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006678-sec-0035"></div> <section id="CD006678-sec-0036"> <h3 class="title">Description of studies</h3> <p>After performing the searches of the electronic databases of CENTRAL (277 studies; some studies were included twice due to updates of the search), MEDLINE (1936 studies; some studies were included twice due to updates of the search) and EMBASE (1258 studies; some studies were included twice due to updates of the search) we excluded 3459 articles based on the title or abstract (or both) since they were not RCTs, did not compare children treated with chemotherapy with children treated without chemotherapy, did not include children at all or did not include children with medulloblastoma. We excluded a further four articles after assessing the full‐text article for reasons described in the <a href="./references#CD006678-sec-0086" title="">Characteristics of excluded studies</a> table. Therefore, we included eight articles that fulfilled all the criteria for considering studies for this review. Two of these eight articles described the same study (<a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>); in one article, children eligible for both our objectives were included (<a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a>; <a href="./references#CD006678-bbs2-0003" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 RTvslowRT/CT</a>). </p> <p>We found no further studies by scanning the reference lists of relevant studies and reviews and the conference proceedings of SIOP, ASPHO and ISPNO. In addition, we identified no ongoing studies by scanning the ongoing trials databases. </p> <p>Therefore, the total number of identified RCTs was eight. Seven studies compared children with medulloblastoma receiving chemotherapy as a part of their treatment with children not receiving chemotherapy as part of their treatment. One study compared children with medulloblastoma receiving standard‐dose RT without chemotherapy with children receiving reduced‐dose RT with chemotherapy. <a href="#CD006678-fig-0001">Figure 1</a> shows the PRISMA flow diagram. </p> <div class="figure" id="CD006678-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram of study selection" data-id="CD006678-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram of study selection</p> </div> </div> </div> <p>Characteristics of included studies are summarised below (for further details see the <a href="./references#CD006678-sec-0085" title="">Characteristics of included studies</a> table). </p> <section id="CD006678-sec-0037"> <h4 class="title">Description of studies comparing treatment including and treatment not including chemotherapy</h4> <p>In the seven RCTs that compared treatment including versus treatment not including chemotherapy the total number of included children was 1080; 499 children in the experimental arm (receiving chemotherapy) and 502 children in the standard arm; for 79 children (from <a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a>), it was unclear to which treatment arm they were randomised. Ages of the children were not mentioned in two studies, and ranged from zero to 20 years in the other RCTs. Chemotherapy was administered during and after RT in three studies, before RT in two studies (thus delaying the start of RT) and after RT in two studies. Chemotherapy regimens contained vincristine in all seven RCTs, but in combination with many different other chemotherapeutics: etoposide in two studies; procarbazine in two studies; predniso(lo)ne in three studies; CCNU in two studies and cisplatin, methotrexate, nitrogen mustard, carboplatin, cyclophosphamide and intrathecal methotrexate and hydrocortisone respectively in one study. CRT doses varied from 25 to 45 Gy; some studies reduced this dose in children younger than either two or three years of age (see <a href="./references#CD006678-sec-0085" title="">Characteristics of included studies</a> table for more information on RT doses in individual studies). Prescribed dose to the fossa posterior was 50 Gy or greater in all studies; however, some studies reduced this dose in children younger than either two or three years. Only two studies mentioned the actual received RT doses. </p> </section> <section id="CD006678-sec-0038"> <h4 class="title">Description of studies comparing treatment with standard‐dose radiotherapy and treatment with reduced‐dose radiotherapy and chemotherapy </h4> <p>Only one study compared children receiving standard‐dose RT without chemotherapy with children receiving reduced‐dose RT with chemotherapy (<a href="./references#CD006678-bbs2-0003" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 RTvslowRT/CT</a>). In children receiving chemotherapy, the start of RT was delayed as compared with children only receiving RT. In this study, 76 children were eligible for evaluation (40 in the standard‐dose RT arm and 36 in the reduced‐dose RT arm). The exact ages of the children were unclear, but to be eligible for inclusion they had to be aged between zero and 16 years of age. According to protocol of the study, in the reduced‐dose arm, the RT dose to the CSA was reduced to 25 Gy instead of 35 Gy, while the tumour‐bearing area received 55 Gy in both arms. In children under two years of age, reduced RT doses were recommended (see <a href="./references#CD006678-sec-0085" title="">Characteristics of included studies</a> table for more information). In the combined treatment arm, chemotherapy was administered before RT. The chemotherapy regimen consisted of vincristine, procarbazine, methotrexate and prednisolone. </p> </section> </section> <section id="CD006678-sec-0039"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD006678-tbl-0002">Table 2</a> for the exact scores per included study. </p> <div class="table" id="CD006678-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of care providers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of outcome assessors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intention‐to‐treat analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Completeness of follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, DFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, DFS and adverse effects: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, EFS and adverse effects: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS and adverse effects: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS and adverse effects: no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, EFS and adverse effects: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0008" title="VanEysJ , ChenT , MooreT , CheekW , SexauerC , StarlingK . Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study. Cancer Treatment Reports1981;65:681‐4. ">Van Eys 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0003" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 RTvslowRT/CT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard‐dose radiotherapy without chemotherapy vs. reduced‐dose radiotherapy and chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: unclear</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>DFS: disease‐free survival; EFS: event‐free survival; OS: overall survival.</p> </div> </div> <section id="CD006678-sec-0040"> <h4 class="title">Risk of bias in studies comparing treatment including and treatment not including chemotherapy </h4> <p>The search identified seven studies.</p> <p>Two studies applied a concealed treatment allocation (<a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>), whereas in five studies this was unclear (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>; <a href="./references#CD006678-bbs2-0008" title="VanEysJ , ChenT , MooreT , CheekW , SexauerC , StarlingK . Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study. Cancer Treatment Reports1981;65:681‐4. ">Van Eys 1981</a>). </p> <p>None of the seven studies blinded care providers and participants to treatment. However, it should be noted that due to the nature of the interventions blinding of care providers and participants was impossible. </p> <p>For blinding of the outcome assessors, we scored each outcome separately, with the exception of OS, since for that outcome blinding was not relevant. Six studies evaluated EFS/DFS (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>): in all studies, it was unclear if the outcome assessor was blinded to treatment. Five studies evaluated adverse effects: in all studies, it was unclear if the outcome assessor was blinded to treatment (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>). </p> <p>We scored the presence of an ITT analysis for each outcome separately. Six studies reported EFS/DFS. Two of the six studies used an ITT analysis (<a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>), whereas this was unclear in four studies (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>). Four studies reported OS. It was unclear if an ITT analysis was used in all four studies (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>; <a href="./references#CD006678-bbs2-0008" title="VanEysJ , ChenT , MooreT , CheekW , SexauerC , StarlingK . Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study. Cancer Treatment Reports1981;65:681‐4. ">Van Eys 1981</a>). Five studies reported adverse effects. One of the five studies used an ITT analysis (<a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>), whereas this was unclear in four studies (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>). </p> <p>We scored participants lost to follow‐up for each outcome separately. Six studies evaluated EFS/DFS. Some participants were lost to follow‐up in one of the six studies (<a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>), whereas in five studies this was unclear (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>). For OS, the number of participants lost to follow‐up was unclear in all four studies (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>; <a href="./references#CD006678-bbs2-0008" title="VanEysJ , ChenT , MooreT , CheekW , SexauerC , StarlingK . Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study. Cancer Treatment Reports1981;65:681‐4. ">Van Eys 1981</a>). Five studies reported adverse effects. Some participants were lost to follow‐up in one study (<a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>), whereas in four studies this was unclear (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>). </p> <p>In conclusion, selection bias (based on concealment of treatment allocation) could not be ruled out in five of the seven included studies. Performance bias (based on blinding of the care provider and participant) could not be ruled out in any of the included studies. Detection bias (based on blinding of the outcome assessor) could not be ruled in any of the studies evaluating EFS/DFS and adverse effects. Attrition bias (based on the use of an ITT analysis and completeness of follow‐up) could not be ruled out in any of the studies evaluating EFS/DFS, OS and adverse effects. </p> </section> <section id="CD006678-sec-0041"> <h4 class="title">Risk of bias in studies comparing treatment with standard‐dose radiotherapy and treatment with reduced‐dose radiotherapy and chemotherapy </h4> <p>The search identified one study.</p> <p>This study applied a concealed treatment allocation. The care provider and participants were not blinded to treatment, but it should be noted that due to the nature of the interventions, blinding of care providers and participants was impossible. For EFS/DFS, it was unclear whether the outcome assessor was blinded to treatment. For EFS/DFS, this study used an ITT analysis. For EFS/DFS, the number of participants lost to follow‐up was unclear. </p> <p>In conclusion, in this study, selection bias (based on concealment of treatment allocation) could be ruled out, whereas performance bias (based on blinding of the care provider and participant), detection bias (based on blinding of the outcome assessor) and attrition bias (based on the use of an ITT analysis and completeness of follow‐up) could not be ruled out. </p> </section> </section> <section id="CD006678-sec-0042"> <h3 class="title" id="CD006678-sec-0042">Effects of interventions</h3> <p>Not all articles allowed data extraction for all outcomes; see <a href="./references#CD006678-sec-0085" title="">Characteristics of included studies</a> table for a more detailed description of the extractable outcomes of each study. </p> <p>In the <a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a>/<a href="./references#CD006678-bbs2-0003" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 RTvslowRT/CT</a> study, children were randomised to one of four treatment arms: 1. standard‐dose RT only, 2. reduced‐dose RT only, 3. chemotherapy plus standard‐dose RT or 4. chemotherapy plus reduced‐dose RT. In children receiving chemotherapy, the start of RT was delayed. For the analyses of treatment including and treatment not including chemotherapy, children receiving RT only (either standard or reduced dose) (treatment arms 1 and 2) were compared with children receiving both chemotherapy and RT (either the standard or reduced dose) (treatment arms 3 and 4). For the analyses of treatment with standard‐dose RT and treatment with reduced‐dose RT and chemotherapy, children from treatment arm 1 were compared with children from treatment arm 4. Children from only treatment arm 2 (reduced‐dose RT only) were not included in the analyses, since comparing reduced‐dose RT without the addition of chemotherapy was not an objective of our review. </p> <section id="CD006678-sec-0043"> <h4 class="title">Studies comparing treatment including and treatment not including chemotherapy</h4> <section id="CD006678-sec-0044"> <h5 class="title">Event‐free survival or disease‐free survival</h5> <p>We were able to extract data on EFS/DFS from six trials (see <a href="./references#CD006678-fig-0006" title="">Analysis 1.1</a>; <a href="#CD006678-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD006678-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.1 Event‐free survival/disease‐free survival (EFS/DFS)." data-id="CD006678-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.1 Event‐free survival/disease‐free survival (EFS/DFS). </p> </div> </div> </div> <p>The trials of <a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a> and <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>, including 300 children, used comparable outcome definitions (i.e. time to recurrence or progression of primary disease or death from any cause; for further details see <a href="./references#CD006678-sec-0085" title="">Characteristics of included studies</a> table) and, therefore, we could pool their results. The meta‐analysis showed no significant difference between treatment including and treatment not including chemotherapy (HR 1.02; 95% CI 0.70 to 1.47; P value = 0.93). There was no heterogeneity (I<sup>2</sup> = 0%). </p> <p>The trials of <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a> and <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>, including 465 children, used comparable outcome definitions (i.e. time to recurrence or death from any cause; for further details see <a href="./references#CD006678-sec-0085" title="">Characteristics of included studies</a> table) and, therefore, we pooled their results. The meta‐analysis showed a significant difference in favour of children treated with chemotherapy (HR 0.70; 95% CI 0.54 to 0.91; P value = 0.007). There was no heterogeneity (I<sup>2</sup> = 0%). </p> <p>In the study of <a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>, including 48 children, no definition for DFS was provided and the definition of EFS used by <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>, including 233 children, was not comparable to the other definitions, therefore, we could not pool the results. However, in both studies there was no significant difference between treatment including and treatment not including chemotherapy (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>: HR 1.67; 95% CI 0.59 to 4.71; P value = 0.34; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>: HR 0.84; 95% CI 0.58 to 1.21; P value = 0.34). For <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>, an ITT analysis was not possible, since 42 children were not randomised (21 in each treatment arm) and 12 children switched between treatment arms after randomisation (six in each treatment arm). </p> </section> <section id="CD006678-sec-0045"> <h5 class="title">Overall survival</h5> <p>We were able to extract data on OS from four trials including 332 children (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>; <a href="./references#CD006678-bbs2-0008" title="VanEysJ , ChenT , MooreT , CheekW , SexauerC , StarlingK . Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study. Cancer Treatment Reports1981;65:681‐4. ">Van Eys 1981</a>). The meta‐analysis showed no significant difference between treatment including and treatment not including chemotherapy (HR 1.06; 95% CI 0.67 to 1.67; P value = 0.80; see <a href="./references#CD006678-fig-0007" title="">Analysis 1.2</a>; <a href="#CD006678-fig-0003">Figure 3</a>). There was no substantial heterogeneity detected (I<sup>2</sup> = 13%). </p> <div class="figure" id="CD006678-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.2 Overall survival." data-id="CD006678-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.2 Overall survival. </p> </div> </div> </div> </section> <section id="CD006678-sec-0046"> <h5 class="title">Adverse effects grade 3 or higher</h5> <p>Six studies evaluated eight different adverse effects grade 3 or higher (see <a href="./references#CD006678-fig-0008" title="">Analysis 1.3</a>; <a href="#CD006678-fig-0004">Figure 4</a>). Of these, only two were long‐term adverse effects (reduction in IQ and secondary malignant disease). The others were all short‐term adverse effects. Treatment‐related mortality was reported in three studies but the other adverse effects were evaluated in only one study. Therefore, we could only perform a meta‐analysis for treatment‐related mortality. </p> <div class="figure" id="CD006678-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.3 Adverse effects." data-id="CD006678-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.3 Adverse effects. </p> </div> </div> </div> <section id="CD006678-sec-0047"> <h6 class="title">Alopecia grade 3</h6> <p>We were able to extract data on acute alopecia grade 3 from one trial including 48 children (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>). There was no significant difference between treatment arms as all children had alopecia grade 3 (RR 1.00; 95% CI 0.92 to 1.08; P value = 1.00). Hair re‐growth occurred in all children six weeks after ending RT and chemotherapy. </p> </section> <section id="CD006678-sec-0048"> <h6 class="title">Reduction in intelligence quotient</h6> <p>We were able to extract data on reduction in IQ from one trial including 48 children (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>). There were 13 cases (reduction of 12% to 21% in comparison with normal siblings) among 27 children randomised to treatment including chemotherapy and 13 cases (reduction of 8% to 20% in comparison with normal siblings) among 21 children randomised to treatment not including chemotherapy. There was no significant difference between treatment arms (RR 0.78; 95% CI 0.46 to 1.30; P value = 0.34). </p> </section> <section id="CD006678-sec-0049"> <h6 class="title">Secondary malignant disease</h6> <p>We were able to extract data on secondary malignant disease from one trial including 286 children (<a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>). The length of follow‐up was not mentioned; the maximal follow‐up was 13 years. There were no cases among 141 children randomised to treatment including chemotherapy and two cases among 145 children randomised to treatment not including chemotherapy. One child developed a meningioma within the area of the posterior fossa boost nine years after treatment; one child developed a low‐grade sarcoma in the occipital region 10 years after treatment. Since one treatment arm experienced no events, we were unable to calculate an RR, but there was no significant difference between treatment arms using the Fisher's exact test (P value = 0.50). </p> </section> <section id="CD006678-sec-0050"> <h6 class="title">Severe infections</h6> <p>We were able to extract data on severe infections from one trial including 233 children (<a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>). There were 11 cases among 115 children randomised to treatment including chemotherapy and two cases among 118 children randomised to treatment not including chemotherapy. There was a significant difference in the occurrence of severe infections in favour of children randomised to treatment not including chemotherapy (RR 5.64; 95% CI 1.28 to 24.91; P value = 0.02). An ITT analysis was not possible, since 42 children were not randomised (21 in each treatment arm) and 12 children switched between treatment arms after randomisation (six in each arm). </p> </section> <section id="CD006678-sec-0051"> <h6 class="title">Haematological toxicity grade 3 or 4</h6> <p>We were able to extract data on haematological toxicity grade 3 or 4 (white blood cells or platelet count, or both) from one trial including 71 patients (<a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>). There were five cases (all grade 4) among 36 children randomised to treatment including chemotherapy and nine cases (eight cases were grade 3; one case was grade 4) among 35 children randomised to treatment not including chemotherapy. In children who received chemotherapy, it was started 4 weeks after the completion of RT. There was no significant difference between treatment groups (RR 0.54; 95% CI 0.20 to 1.45; P value = 0.22). </p> </section> <section id="CD006678-sec-0052"> <h6 class="title">Hepatotoxicity grade 3</h6> <p>We were able to extract data on hepatotoxicity grade 3 from one trial including 71 patients (<a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>). There was one case among 36 children randomised to treatment including chemotherapy and no cases among 35 children randomised to treatment not including chemotherapy. Since one treatment arm experienced no events, we were unable to calculate an RR, but there was no significant difference between treatment groups using the Fisher's exact test (P value = 1.00). </p> </section> <section id="CD006678-sec-0053"> <h6 class="title">Fever and neutropenia</h6> <p>We were able to extract data on fever and neutropenia from one trial including 71 patients (<a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>). There were seven cases among 36 children randomised to treatment including chemotherapy and no cases among 35 children randomised to treatment not including chemotherapy. Since one treatment arm experienced no events, we were unable to calculate an RR, but there was a significant difference in favour of treatment not including chemotherapy using the Fisher's exact test (P value = 0.01). </p> </section> <section id="CD006678-sec-0054"> <h6 class="title">Treatment‐related mortality</h6> <p>We were able to extract data on treatment‐related mortality from three trials including 284 children (<a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>; <a href="./references#CD006678-bbs2-0008" title="VanEysJ , ChenT , MooreT , CheekW , SexauerC , StarlingK . Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study. Cancer Treatment Reports1981;65:681‐4. ">Van Eys 1981</a>). There were four cases among 142 children randomised to treatment including chemotherapy and one case among 142 children randomised to treatment not including chemotherapy. Children in the chemotherapy arm died from pneumococcal sepsis and pericarditis (one child), septicaemia and toxic dilation of the gastrointestinal tract (one child), sepsis (one child) and life‐threatening myelosuppression (one child, but the exact cause of death was not ascertained). One child in the treatment not including chemotherapy arm died from disseminated intravascular coagulopathy and meningitis. The meta‐analysis showed no significant difference between treatment groups (RR 2.37; 95% CI 0.43 to 12.98; P value = 0.32). There was no heterogeneity (I<sup>2</sup> = 0%). </p> </section> </section> <section id="CD006678-sec-0055"> <h5 class="title">Quality of life</h5> <p>None of the studies evaluated quality of life.</p> </section> </section> <section id="CD006678-sec-0056"> <h4 class="title">Sensitivity analyses</h4> <p>The results of the sensitivity analyses were consistent among the trials and did not differ from the overall analyses. </p> </section> <section id="CD006678-sec-0057"> <h4 class="title">Subgroup analyses</h4> <p>Three studies presented adequate survival data on younger/older children (<a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>), or high‐risk/non‐high‐risk children (<a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>). Since definitions used for high‐risk/non‐high‐risk children were not comparable between the studies, we could not pool results. Thus, we have summarised the results descriptively (i.e. as presented in the individual articles). </p> <section id="CD006678-sec-0058"> <h5 class="title">Younger versus older children</h5> <p>One study reported EFS/DFS and OS for three age groups: aged three to seven, eight to 11 and 12 to 16 years. There was no significant effect of age on outcome in relation to EFS/DFS (P value = 0.44) or OS (P value = 0.54) (<a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>). </p> </section> <section id="CD006678-sec-0059"> <h5 class="title">High‐risk versus non‐high‐risk children</h5> <p>In one study, for the 113 children with early‐stage disease (T1 and T2), chemotherapy had no effect on EFS/DFS (<a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>). However, with advanced disease (T3 and T4), the 91 children who received chemotherapy had significantly better EFS/DFS than the 72 children who did not receive chemotherapy (P value = 0.002). </p> <p>In one study, there was no benefit in EFS/DFS from chemotherapy in 67 children who had tumour stage T1‐2/M0 and in 124 children with tumour stage T3‐4/M0 (P value = 0.27; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>). There were too few children with low T‐stage and advanced M‐stage disease (T3 or 4, M1 to 3; 12 children) for analysis, but the group with advanced T‐stage and M‐stage disease (T3 or T4, M1 to M3) showed a striking effect of chemotherapy (46% with chemotherapy versus 0% with no chemotherapy; P value = 0.006). It should be noted that these data were not from an ITT analysis. </p> </section> </section> <section id="CD006678-sec-0060"> <h4 class="title">Studies comparing treatment with standard‐dose radiotherapy and treatment with reduced‐dose radiotherapy and chemotherapy </h4> <section id="CD006678-sec-0061"> <h5 class="title">Event‐free survival or disease‐free survival</h5> <p>One study, including 76 children, reported data on EFS/DFS (<a href="./references#CD006678-bbs2-0003" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 RTvslowRT/CT</a>). There was no significant difference between treatment with standard‐dose RT and treatment with reduced‐dose RT and chemotherapy (HR 1.54; 95% CI 0.81 to 2.94; P value = 0.19) (see <a href="./references#CD006678-fig-0009" title="">Analysis 2.1</a>; <a href="#CD006678-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD006678-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Treatment including reduced‐dose radiotherapy (RT) and chemotherapy versus treatment including standard‐dose RT, outcome: 2.1 Event‐free survival/disease‐free survival (EFS/DFS)." data-id="CD006678-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Treatment including reduced‐dose radiotherapy (RT) and chemotherapy versus treatment including standard‐dose RT, outcome: 2.1 Event‐free survival/disease‐free survival (EFS/DFS). </p> </div> </div> </div> </section> <section id="CD006678-sec-0062"> <h5 class="title">Other outcomes</h5> <p>We found no studies comparing the effects of treatment with standard‐dose RT and treatment with reduced‐dose RT and chemotherapy on OS, adverse effects or quality of life. </p> </section> <section id="CD006678-sec-0063"> <h5 class="title">Subgroup analyses</h5> <p>We found no data on younger/older children and high‐risk/non‐high‐risk children; thus, we could not perform subgroup analyses. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006678-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006678-sec-0064"></div> <p>This systematic review evaluated the current state of evidence on the effectiveness of treatment including chemotherapy compared with treatment not including chemotherapy in children with medulloblastoma. Furthermore, we evaluated the current state of evidence on the effectiveness of treatment with standard‐dose RT compared with treatment with reduced‐dose RT and chemotherapy in children with medulloblastoma. We only included RCTs since it is widely recognised that an RCT is the only study design that can produce unbiased evidence on the use of different treatment options, provided that the design and execution are adequate. </p> <section id="CD006678-sec-0065"> <h3 class="title" id="CD006678-sec-0065">Treatment including chemotherapy compared with treatment not including chemotherapy</h3> <p>We identified seven RCTs, published between 1981 and 2005 (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>; <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>; <a href="./references#CD006678-bbs2-0008" title="VanEysJ , ChenT , MooreT , CheekW , SexauerC , StarlingK . Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study. Cancer Treatment Reports1981;65:681‐4. ">Van Eys 1981</a>). Unfortunately, different definitions of study end points, numerous chemotherapy regimens and doses (none of which would be considered standard of care today), changes inherent to three decades of technological and histo/biological knowledge and the fact that, in most studies, results for different risk groups were not reported separately were major obstacles in comparing the results of the different studies. </p> <p>The studies used three different definitions of EFS and DFS, and one study provided no definition of DFS. This made pooling of the results of all studies impossible. The definitions of other outcome measures (OS and adverse events) were comparable between studies. Furthermore, none of the studies used exactly the same chemotherapy schedule. Eleven different drugs were administered in seven different regimens and the actual received doses of chemotherapy were not mentioned in most of the studies. For evaluation of the effect of chemotherapy, this is important information. The lack of efficacy of a certain chemotherapy regimen might be due to dose reduction due to toxicity. In that respect, it is important to realise that the inclusion period encompassed 30 years. In this time, supportive care has improved substantially and the expectation might thus be that in later time periods, stricter adherence to the chemotherapy protocols was possible. Furthermore, over three decades, both diagnosis and treatment have evolved substantially: improved imaging techniques (not all included studies used magnetic resonance imaging as imaging modality) and different staging criteria. In addition, neurosurgical and RT procedures have changed substantially. </p> <p>Only one study provided information on histological subtypes of medulloblastoma, that is, nodular/desmoplastic versus classical variants, and no study mentioned large cell/anaplastic variants. Evaluating the effect of chemotherapy by considering all these subtypes as one group may result in under‐ or overestimating the effectiveness of chemotherapy. No study provided information on molecular characteristics of the medulloblastomas. New molecular subgroups have emerged that show clear differences in prognosis of children with medulloblastoma (<a href="./references#CD006678-bbs2-0047" title="TaylorMD , NorthcottPA , KorshunovA , RemkeM , ChoY , CliffordSC , et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica2012;123:465‐72. ">Taylor 2012</a>). The included studies did not examine these molecular characteristics. This is likely to have influenced the overall results of the included studies, as did the fact that, in most studies, different risk groups were not analysed separately. </p> <p>With regard to EFS/DFS, pooling of the trials of <a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a> and <a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a> including 300 children showed no significant advantage of the addition of chemotherapy; in these studies, EFS/DFS were defined as time to recurrence or progression of primary disease or death from any cause. This result was confirmed in two individual studies that we could not pool (<a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a>; <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>). In contrast, the meta‐analysis of the studies of <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a> and <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a> including 465 children showed a significant difference in favour of treatment with chemotherapy; in these studies, EFS/DFS were defined as time to recurrence of primary disease or death from any cause and not including disease progression as an event might not be optimal. It should be noted that in the study of <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>, the difference in DFS reached statistical significance while the study was running, but, due to late relapses in the chemotherapy arm, this significance was no longer evident with longer follow‐up. </p> <p>The discordance between the two meta‐analyses is difficult to explain. Whether the results in favour of chemotherapy in the second meta‐analysis can be explained by the fact that the studies of <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a> and <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a> did not include progression of disease in their definition of EFS/DFS cannot be ruled out. The Primitive Neuroectodermal Tumour Study (PNET)‐3 study of <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a> advised that people progressing under chemotherapy would go for immediate RT, but no actual data were given on the exact number of participants that progressed. It would be interesting to take into account the number of participants that progressed, and determine whether addition of chemotherapy would still give a significant EFS/DFS advantage. </p> <p>Regarding OS, we pooled the results of four studies including 332 children. There was no significant difference in OS between treatment with and without chemotherapy. </p> <p>Adverse effects (grade 3 or higher) were scarcely reported. Most adverse events were only mentioned in one RCT, or data were only provided for the chemotherapy arm and not for the RT only arm. Thus, as the risk of underreporting was real, caution must be taken in interpreting these results. Of eight different adverse effects grade 3 or higher, two (severe infections and fever/neutropenia) showed a significant difference in favour of the treatment not including chemotherapy. For the six other adverse effects (i.e. acute alopecia, reduction in IQ, secondary malignant disease, haematological toxicity, hepatotoxicity (all evaluated in one study); and treatment‐related mortality (based on a meta‐analysis of three studies including 284 children)), there was no significant difference between the treatment arms. However, in a small subgroup (26%) of participants included in the PNET‐3 study (i.e. the same protocol as in the <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a> study), which was included in this review, permanent cranial alopecia was more prevalent in children receiving chemotherapy and RT compared with people receiving only RT (<a href="./references#CD006678-bbs2-0012" title="RogersS , DonachieP , SugdenE , SharpeG , EnglishM , RobinsonK , et al. Comparison of permanent hair loss in children with standard risk PNETS of the posterior fossa following radiotherapy alone or chemotherapy and radiotherapy after surgical resection. Pediatric Blood and Cancer2011;57(6):1074‐6. ">Rogers 2011</a>). The number of cases of secondary malignant disease in the study of <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a> (two cases of secondary malignant disease on 286 children treated) seems low in comparison to the Children's Oncology Group (COG) study, which reported 14 cases of secondary malignant disease at eight years of follow‐up on 379 children treated (<a href="./references#CD006678-bbs2-0036" title="PackerRJ , HolmesE , ZhouT , GajjarA , VezinaG . Second malignant neoplasms (SMNS) following ‘successful’ treatment of non‐disseminated medulloblastoma (MB): a 10‐year follow‐up of patients treated on a COG study. Neuro‐Oncology2010;12(6):ii8. ">Packer 2010</a>). Even taking into account the lower survival in the study of <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>, and thus the lower number of children at risk for developing a secondary malignant disease, the discrepancy remains. In the study of <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>, 66% of children were lost to follow‐up by nine years. This might explain these results. </p> <p>The health status of a subgroup of children (i.e. part of the surviving UK participants) included in the study of <a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>, together with some participants who did receive the same treatment in a non‐randomised manner, was reported separately (<a href="./references#CD006678-bbs2-0015" title="BullKS , SpoudeasHA , YadegarfarG , KennedyCR . Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow‐up study in PNET3 trial survivors‐on behalf of the CCLG (formerly UKCCSG). Journal of Clinical Oncology2007;25(27):4239‐45. ">Bull 2007</a>). In these participants, the addition of chemotherapy to CSRT was associated with a significant decrease in health status (assessed at a mean of 7.2 years after diagnosis). Unfortunately, quality of life was not evaluated in any of the included articles in this review. </p> <p>In the individual studies, different subgroups were evaluated. One study provided survival data on children in different age groups (three to seven, eight to 11 and 12 to 16 years of age); there was no significant effect of age in relation to EFS/DFS and OS (<a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a>). However, no comparison was made for children younger or older than three years of age, which is a broadly used cut‐off point in determining risk group in children. Two trials examined EFS/DFS for the subgroups high‐risk versus non‐high‐risk, but, as the definition of the risk groups was different in the two studies, we could not pool the results (<a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>; <a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a>). The individual study results showed no significant difference in EFS/DFS between the treatment arms in some subgroups, while in other subgroups (all children with advanced disease, but differently defined) children receiving chemotherapy responded significantly better. The criteria for defining standard‐risk disease versus high‐risk disease have changed since 1990, but re‐assigning people of those studies into risk groups that are commonly used today was not possible because of lack of information. As a result, no definitive conclusions were made regarding the effect of chemotherapy in the different subgroups as they would be classified in contemporary protocols. </p> <p>'No evidence of effect', as identified in this review, is not the same as 'evidence of no effect'. A benefit of chemotherapy cannot be excluded. The reason that some studies did not identify a significant difference between study arms could, besides reasons mentioned earlier, also be due to the number of participants included in these studies being too small to detect a difference between the treatment arms (i.e. low power). Furthermore, the length of follow‐up could have been too short to detect a significant difference between the treatment arms. For example, for secondary malignant disease, the maximal follow‐up was 13 years, but it is possible that in participants with a shorter follow‐up, a secondary malignant disease has not yet developed, but will develop when follow‐up increases. </p> <p>The risk of bias in the included studies was difficult to assess due to a lack of reporting. As a result, we could not rule out the presence of selection bias, performance bias, detection bias and attrition bias. However, at the moment this is the best available evidence of RCTs comparing the effectiveness of treatment including chemotherapy compared with treatment not including chemotherapy in children with medulloblastoma. With regard to performance bias, it should be noted that due to the nature of the interventions, blinding of care providers and participants was virtually impossible. In this review, we only performed ITT analyses, since they provide the most realistic and unbiased answer to the question of clinical effectiveness (<a href="./references#CD006678-bbs2-0029" title="LachinJM . Statistical considerations in the intent‐to‐treat principle. Controlled Clinical Trials2000;21:167‐89. ">Lachin 2000</a>; <a href="./references#CD006678-bbs2-0030" title="LeeYJ , EllenbergJH , HirtzDG , NelsonKB . Analysis of clinical trials by treatment actually received: is it really an option?. Statistics in Medicine1991;10:1595‐605. ">Lee 1991</a>). However, for <a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a>, an ITT analysis was not possible, and therefore, we performed an as‐treated analysis. </p> <p>The results of this systematic review must be viewed in the context of the complete therapy (e.g. the effect of surgery and CSRT, and the different chemotherapy protocols used (such as different agents or different doses, or both)). We have pooled the results of all eligible studies, but, as stated before, the above mentioned items differed between the studies. As a result, in this systematic review, we can only provide conclusions on the concept of treatment including chemotherapy versus treatment not including chemotherapy. We cannot make conclusions with regard to specific treatment options (such as type of surgery, RT fields and doses, different chemotherapeutic agents and doses). </p> </section> <section id="CD006678-sec-0066"> <h3 class="title" id="CD006678-sec-0066">Treatment with standard‐dose radiotherapy compared with treatment with reduced‐dose radiotherapy and chemotherapy </h3> <p>We identified one RCT, published in 1995, including 76 children (<a href="./references#CD006678-bbs2-0003" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 RTvslowRT/CT</a>). The treatment protocol used in the study would not be considered standard of care today. Only EFS/DFS was evaluated and there was no significant difference between treatment arms. Unfortunately, there was no information on effects on OS, adverse effects and quality of life or for different subgroup analyses. </p> <p>It should be noted that results of only a small proportion of the eligible participants have been presented (see <a href="./references#CD006678-sec-0085" title="">Characteristics of included studies</a> table), and, as a result, there was a high risk of attrition bias. The same obstacles in interpreting the results as in the previous studies were encountered: the actual received doses of chemotherapy were not mentioned and the study did not provide information on histological subtypes of medulloblastoma or on molecular characteristics. </p> <p>In this study, we ruled out selection bias, whereas we could not rule out performance bias, detection bias and attrition bias. However, at the moment this is the best‐available evidence of RCTs comparing the effectiveness of treatment with standard‐dose RT with treatment with reduced‐dose RT and chemotherapy in children with medulloblastoma. With regard to performance bias, it should be noted that due to the nature of the interventions, blinding of care providers and participants was virtually impossible. </p> <p>In addition, even though RCTs are the highest level of evidence, it should be recognised that data from non‐randomised studies are available, for example on the use of chemotherapy only in very young children. The results are promising for children without metastatic disease (<a href="./references#CD006678-bbs2-0022" title="GrillJ , Sainte‐RoseC , JouvetA , GentetJC , LejarsO , FrappazD , et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncology2005;6:573‐80. ">Grill 2005</a>; <a href="./references#CD006678-bbs2-0042" title="RutkowskiS , BodeU , DeinleinF , OttensmeierH , Warmuth‐MetzM , SoerensenN , et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. New England Journal of Medicine2005;352:978‐86. ">Rutkowski 2005</a>), which is important since without craniospinal irradiation fewer long‐term adverse effects will occur. Furthermore, it should be noted that in this systematic review, we did not evaluate the effect of reductions in radiation fields (at the tumour bed) and RT dose other than the definitions we used in this review for standard and reduced dose (as described in the <a href="#CD006678-sec-0017">Methods</a> section). These issues are also important in further optimising the treatment of children with medulloblastoma and should be kept in mind. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006678-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Flow diagram of study selection" data-id="CD006678-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram of study selection</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006678-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.1 Event‐free survival/disease‐free survival (EFS/DFS)." data-id="CD006678-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.1 Event‐free survival/disease‐free survival (EFS/DFS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006678-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.2 Overall survival." data-id="CD006678-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.2 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006678-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.3 Adverse effects." data-id="CD006678-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Chemotherapy versus no chemotherapy, outcome: 1.3 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006678-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Treatment including reduced‐dose radiotherapy (RT) and chemotherapy versus treatment including standard‐dose RT, outcome: 2.1 Event‐free survival/disease‐free survival (EFS/DFS)." data-id="CD006678-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Treatment including reduced‐dose radiotherapy (RT) and chemotherapy versus treatment including standard‐dose RT, outcome: 2.1 Event‐free survival/disease‐free survival (EFS/DFS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006678-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Treatment including chemotherapy versus treatment not including chemotherapy, Outcome 1 Event‐free survival/disease‐free survival (EFS/DFS)." data-id="CD006678-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Treatment including chemotherapy versus treatment not including chemotherapy, Outcome 1 Event‐free survival/disease‐free survival (EFS/DFS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references#CD006678-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006678-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Treatment including chemotherapy versus treatment not including chemotherapy, Outcome 2 Overall survival." data-id="CD006678-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Treatment including chemotherapy versus treatment not including chemotherapy, Outcome 2 Overall survival. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references#CD006678-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006678-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Treatment including chemotherapy versus treatment not including chemotherapy, Outcome 3 Adverse effects." data-id="CD006678-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Treatment including chemotherapy versus treatment not including chemotherapy, Outcome 3 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references#CD006678-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006678-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/urn:x-wiley:14651858:media:CD006678:CD006678-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_t/tCD006678-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Treatment including reduced‐dose radiotherapy (RT) and chemotherapy versus treatment including standard‐dose RT, Outcome 1 Event‐free survival/disease‐free survival (EFS/DFS)." data-id="CD006678-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Treatment including reduced‐dose radiotherapy (RT) and chemotherapy versus treatment including standard‐dose RT, Outcome 1 Event‐free survival/disease‐free survival (EFS/DFS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references#CD006678-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/media/CDSR/CD006678/image_n/nCD006678-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD006678-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for the assessment of risk of bias in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk of bias item</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Implementation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Adequate</i> : use of randomisation method that did not allow investigator and participant to know or influence the allocation of treatment before eligible participants entered the study<br/> <i>Inadequate</i> : use of alternate medical record numbers or unsealed envelopes as randomisation method, or there was information in the study indicating that investigators or participants could have influenced the allocation of treatment, or both<br/> <i>Unclear</i>: randomisation stated but no information on method used was available </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinding of care providers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Performance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate information about blinding must have been provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinding of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Performance bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate information about blinding must have been provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blinding of outcome assessors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Detection bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate information about blinding must have been provided</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intention‐to‐treat analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attrition bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Yes</i> : all participants were analysed in the treatment group to which they were randomised, regardless of whether or not they received the allocated intervention<br/> <i>No</i> : some participants (&lt; 5%, 5‐10%, 11‐20%, &gt; 20%) were not analysed in the treatment group to which they were randomised because they did not receive study intervention, they withdrew from the study or because of protocol violation<br/> <i>Unclear</i>: inability to determine if participants were analysed according to the intention‐to‐treat principle </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Completeness of follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attrition bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percentage of participants excluded or lost to follow‐up (&lt; 5%, 5‐10%, 11‐20%, &gt; 20%) should be stated </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Criteria for the assessment of risk of bias in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006678-tbl-0002"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comparison</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Allocation concealment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of care providers</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of participants</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Blinding of outcome assessors</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intention‐to‐treat analysis</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Completeness of follow‐up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0001" title="Abd El‐AalHH , MokhtarMM , HabibEE , El‐KashefAT , FahmyES . Medulloblastoma: conventional radiation therapy in comparison to chemoradiation therapy in the post‐operative treatment of high‐risk patients. Journal of the Egyptian National Cancer Institute2005;17(4):301‐7. ">Abd El‐Aal 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, DFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, DFS and adverse effects: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0002" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 CT vs no CT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0004" title="EvansAE , JenkinRDT , SpostoR , OrtegaJA , WilsonCB , WaraW , et al. The treatment of medulloblastoma: results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. Journal of Neurosurgery1990;72:572‐82. ">Evans 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0005" title="KrischerJP , RagabAH , KunL , KimTH , LaurentJP , BoyettJM , et al. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. Journal of Neurosurgery1991;74:905‐9. ">Krischer 1991</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, EFS and adverse effects: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0006" title="TaitDM , Thornton‐JonesH , BloomHJ , LemerleJ , Morris‐JonesP . Adjuvant chemotherapy for medulloblastoma: the first multi‐centre control trial of the International Society of Paediatric Oncology (SIOP I). European Journal of Cancer1990;26(4):464‐9. ">Tait 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS and adverse effects: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>DFS and adverse effects: no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0007" title="TaylorRE , BaileyCC , RobinsonK , WestonCL , EllisonD , IronsideJ , et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET‐3 study. Journal of Clinical Oncology2003;21(8):1581‐91. TaylorRE , BaileyCC , RobinsonKJ , WestonCL , EllisonD , IronsideJ , et al. Impact of radiotherapy parameters on outcome in the international society of paediatric oncology/United Kingdom children's cancer study group PNET‐3 study of preradiotherapy chemotherapy for M0‐M1 medulloblastoma. International Journal of Radiation Oncology, Biology, Physics2004;58(4):1184‐93. ">Taylor 2003/4</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, EFS and adverse effects: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS, EFS and adverse effects: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0008" title="VanEysJ , ChenT , MooreT , CheekW , SexauerC , StarlingK . Adjuvant chemotherapy for medulloblastoma and ependymoma using IV vincristine, intrathecal methotrexate, and intrathecal hydrocortisone: a Southwest Oncology Group study. Cancer Treatment Reports1981;65:681‐4. ">Van Eys 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chemotherapy vs. no chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not applicable for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OS: unclear</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD006678-bbs2-0003" title="BaileyCC , GnekowA , WellekS , JonesM , RoundC , BrownJ , et al. Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II. Medical and Pediatric Oncology1995;25(3):166‐78. ">Bailey 1995 RTvslowRT/CT</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Standard‐dose radiotherapy without chemotherapy vs. reduced‐dose radiotherapy and chemotherapy </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adequate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EFS: unclear</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>DFS: disease‐free survival; EFS: event‐free survival; OS: overall survival.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/full#CD006678-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006678-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Treatment including chemotherapy versus treatment not including chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Event‐free survival/disease‐free survival (EFS/DFS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 EFS including progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.70, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 EFS/DFS not including progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.54, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Definition of DFS not provided</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.67 [0.59, 4.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 EFS in participants without sepsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.58, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.67, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Alopecia grade 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.92, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Reduction in intelligence quotient (IQ)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.46, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Severe infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.64 [1.28, 24.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Haematological toxicity grade 3 or 4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.20, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Treatment‐related mortality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [0.43, 12.98]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Treatment including chemotherapy versus treatment not including chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references#CD006678-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006678-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Treatment including reduced‐dose radiotherapy (RT) and chemotherapy versus treatment including standard‐dose RT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Event‐free survival/disease‐free survival (EFS/DFS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.54 [0.81, 2.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Treatment including reduced‐dose radiotherapy (RT) and chemotherapy versus treatment including standard‐dose RT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006678.pub2/references#CD006678-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006678.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006678-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006678-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD006678-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ru#CD006678-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006678\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006678\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006678\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006678\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006678\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xsb6SJyC&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006678.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006678.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006678.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006678.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006678.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727487802"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006678.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727487806"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006678.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ead44c805f573',t:'MTc0MDcyNzQ4OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 